Search
Assembly Biosciences Inc
ASMBAdd to Watchlist
27.740USD
+1.050+3.93%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
549.72MMarket Cap
303.30P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.93%
5 Days
+3.74%
1 Month
+12.90%
6 Months
-17.80%
Year to Date
-18.44%
1 Year
+52.92%
Key Figures
26.750Open
27.770High
199.26KVolume
303.30P/E TTM
LossP/E Dynamic
--Dividend TTM
1.25%Turnover Ratio
26.690Prev. Close
26.410Low
2.77MTurnover
LossP/E Static
2.22P/B
0.00%Div Yield TTM
-3.82%ROA
39.70552wk High
0.73Volume Ratio
-40.18MNet Profit
15.89MShares
0.0915EPS TTM
1.09Beta
-5.66%ROE
13.81052wk Low
5.10%Amplitude
100.00%Gross Margin
549.72MMarket Cap
2.33Reward/Risk
3.71%Risk Rate
TradingKey Stock Score of Assembly Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Assembly Biosciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 48.75.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Assembly Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Assembly Biosciences Inc Highlights
StrengthsRisks
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 909.40% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.30M.
Overvalued
The company’s latest PE is 303.30, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.26M shares, increasing 4.47% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 348.54K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.26.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
48.750
Target Price
+82.65%
Upside Space
Assembly Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Assembly Biosciences Inc Info
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Ticker SymbolASMB
CompanyAssembly Biosciences Inc
CEO
Websitehttps://www.assemblybio.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Assembly Biosciences Inc (ASMB)?
The current price of Assembly Biosciences Inc (ASMB) is 27.74.
What is the symbol of Assembly Biosciences Inc?
The ticker symbol of Assembly Biosciences Inc is ASMB.
What is the 52-week high of Assembly Biosciences Inc?
The 52-week high of Assembly Biosciences Inc is 39.70.
What is the 52-week low of Assembly Biosciences Inc?
The 52-week low of Assembly Biosciences Inc is 13.81.
What is the market capitalization of Assembly Biosciences Inc?
The market capitalization of Assembly Biosciences Inc is 440.85M.
Is Assembly Biosciences Inc (ASMB) currently rated as Buy, Hold, or Sell?
According to analysts, Assembly Biosciences Inc (ASMB) has an overall rating of STRONG BUY, with a price target of 48.75.
What is the Earnings Per Share (EPS TTM) of Assembly Biosciences Inc (ASMB)?
The Earnings Per Share (EPS TTM) of Assembly Biosciences Inc (ASMB) is -0.55.